In unpredictable markets, resilience isn’t optional, it’s essential. This piece explores how economic and regulatory shocks test corporate strategies and why embedding agility and cross-functional coordination into CI frameworks empowers companies to weather turbulence and stay nimble.
Beyond the Dashboard: Next-Level Foresight through Primary Research Driven Early Warning System
What if you could anticipate competitor moves, market shifts and changing customer preferences, not react to them? Discover how integrating primary research into your Early Warning System empowers predictive intelligence, transforming reactive monitoring into proactive strategy.
Pharma CI Conference 2024: Comprehensive Summary Report
At the Pharma CI Conference (Sept 25–26, 2024), leaders discussed how shifts like the IRA’s impact on drug pricing, AI in R&D, and shifting regulatory regimes are reshaping life sciences CI. Read this summary to grasp the conference’s breakout trends and strategic implications.
Best Practices in Competitive Landscape Development
Combine secondary data (clinical registries, financial filings) with primary intelligence (expert interviews) to build a 360° view of your competitive environment. These integrated methods enable triangulated, validated insights into competitor strategies, commercial infrastructure, and trial dynamics
How a Competitor Pricing Analysis Guarantees Competitive Advantage
Competitive insight isn’t one-size-fits-all. We delve into multi‑pronged data collection, covering pricing, packaging, discounts, and bundling, to identify optimal tactics across segments and contexts. This post breaks down how to benchmark pricing strategies and create differentiated value propositions.
Know where your competitors are conducting clinical trials!
Through analysis of IO clinical trials (2018–2022), we reveal how top‑20 pharma concentrate on mAb trials globally, while smaller firms explore innovative modalities like BsAb and CAR‑T, and how China is emerging as an IO hub. These patterns offer strategic cues for reshaping your trial portfolio and R&D focus.
Accelerated Approval Pathway Part 1
This first article, part of a three-post series, focusses on need for such a meeting and underlines the impact of accelerated approvals in the field of Oncology.
Competitive Intelligence Scoping
Increasingly, employees at all levels of the organization are being called upon to support the competitive intelligence function. Will you be ready? Will you know what to say? What to ask? Read more to learn how to increase effectiveness by simply asking the right questions.
COVID-19 Impact on Pharma: A Q2 Earnings Narrative
The COVID-19 pandemic has had a very strong impact on all global economies across multiple sectors. Its impact on the US Pharma industry was significant in the first quarter, causing most companies to adjust and realign their businesses in response to the outbreak. The pandemic not only had a direct impact on Q1 revenues, but also affected overall drug development …
Strategic Considerations for a World in Flux
Before COVID-19 transpired executives were concerned with their strategic assumptions and the results of getting them wrong. A February 2020 Gartner study cited lack of confidence in strategic assumptions as the leading corporate risk among senior executives across a diverse set of industries and global geographies in Q4 2019. A strategic assumption can be defined as the unstated belief that something is likely to occur to enable an achievable strategic goal. Depending on the …